Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine

OBJECTIVE: Disease-modifying anti-rheumatic drugs (DMARDs) that treat rheumatoid arthritis (RA) may reduce immune responses to COVID-19 vaccination. We compared humoral and cell-mediated immunity before and after a 3rd dose of mRNA COVID vaccine in RA subjects. METHODS: RA patients that received 2 d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tedeschi, Sara K., Solomon, Daniel H., Chen, Yuezhou, Ellrodt, Jack, Whelan, Mary Grace, Stratton, Jacklyn, Hayashi, Keigo, Whiteman, Noah Benjamin, Chen, Lin, Adejoorin, Ifeoluwakiisi, Marks, Kathryne E., Gomez-Rivas, Emma, Rao, Deepak A., Jonsson, A. Helena, Wesemann, Duane R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911151/
https://www.ncbi.nlm.nih.gov/pubmed/36796211
http://dx.doi.org/10.1016/j.semarthrit.2023.152177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911151/
https://www.ncbi.nlm.nih.gov/pubmed/36796211
http://dx.doi.org/10.1016/j.semarthrit.2023.152177

Ejemplares similares